For Family Members and Loved Ones: A Canadian Guide to Psychedelic-Assisted Therapy

Someone you love is considering, or has already started, psychedelic-assisted therapy in Canada. You have questions: Is this safe? Is it approved? What can I do to help? What should I never do? This guide is written for spouses, partners, parents, adult children, siblings, and close friends who want to understand the process and be genuinely useful.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

If your loved one is in crisis right now

• 9-8-8 Suicide Crisis Helpline: call or text 988 (Canada-wide, 24/7)
• Talk Suicide Canada: 1-833-456-4566 (24/7) or text 45645 (4 PM–midnight ET)
• In Quebec: 1-866-APPELLE (1-866-277-3553)
• Kids Help Phone (under 30), 1-800-668-6868 or text CONNECT to 686868
• In imminent danger: call 911 or go to the nearest emergency department

Key takeaways

• Psychedelic-assisted therapy in Canada is real and regulated. Spravato (esketamine) is Health Canada-approved for treatment-resistant depression. Off-label ketamine has RCT support. Psilocybin and MDMA are accessed only through Health Canada's case-by-case authorization, initiated by a physician, and are investigational.
• Your role is support, not interpretation. Family members are part of the care system; they are not the clinical team.
• Practical day-of support is the most concrete thing you can do. The 24-hour no-driving rule after dissociative or psychedelic dosing means your loved one needs a ride home.
• You are generally not in the dosing room for adult patients in standard protocols. The dosing space is for the patient and trained therapist.
• What not to do matters as much as what to do. Interpreting the experience, pressuring for outcomes, and demanding session details are common missteps.
• Caregiver burden is real. Your own mental health needs attention, too.
• Honest framing: psychedelic-assisted therapy may help, may produce partial response, or may not produce a response. It is part of ongoing care, not a one-shot fix.
• Standard contraindications a family member should be aware of: personal or family history of psychosis; bipolar I disorder; pregnancy or breastfeeding; certain cardiovascular conditions. The clinical team screens for these at intake.

Family members are welcome at ATMA CENA's information calls, with the patient's consent. If you want to understand the pathway your loved one is being offered, book a free information call.

---

What is psychedelic-assisted therapy, and is it legitimate?

Psychedelic-assisted therapy in Canada is a structured clinical process combining a psychoactive medication with psychological preparation and integration. It is delivered in licensed clinics, hospital programs, and settings authorized by Health Canada on a case-by-case basis, under physician and therapist supervision. It is not the same as recreational use, retreat tourism, or unsupervised self-administration.

The regulatory picture by substance:

Substance	Canadian status	Typical indication
Spravato (esketamine)	Health Canada-approved (May 2020)	Treatment-resistant depression (TRD); recommended for adults under 65 [Health Canada 2025]
Ketamine (off-label)	HC-approved as anaesthetic; psychiatric use is off-label	TRD, PTSD, suicidality, off-label [Anand 2023]
Psilocybin	Schedule III; case-by-case Health Canada access	End-of-life distress; TRD, investigational [Goodwin 2022]
MDMA	Schedule I; case-by-case Health Canada access	PTSD, investigational [Mitchell 2021]

Legitimate, supervised psychedelic-assisted therapy in Canada exists. If your loved one is being offered care at a credentialed clinic with physician oversight, that is a meaningfully different context from unregulated settings.

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada authorization, granted on a case-by-case basis and initiated by a physician; approval is not guaranteed. This access is primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness (psilocybin), or PTSD (MDMA). [Health Canada 2022]

---

What the evidence actually says

The evidence base varies by condition. The honest picture:

• Treatment-resistant depression (TRD): Spravato has Phase 3 program data (TRANSFORM-1/2/3, SUSTAIN-1/2 [Health Canada 2025]). Off-label ketamine has the Anand 2023 ELEKT-D trial showing ketamine non-inferior to ECT in non-psychotic TRD [Anand 2023]. Psilocybin for TRD has Goodwin 2022 in NEJM [Goodwin 2022].
• PTSD: MDMA-assisted therapy has Mitchell 2021 and 2023 (MAPP1/MAPP2 in Nature Medicine), Phase 3 trials with significant improvement vs. placebo-plus-therapy [Mitchell 2021; Mitchell 2023].
• End-of-life distress: Psilocybin has Griffiths 2016 and Ross 2016 in Journal of Psychopharmacology, both showing substantial, sustained decreases in cancer-related depression and anxiety at 6-month follow-up [Griffiths 2016; Ross 2016]. This is among the strongest single-substance, single-indication evidence bases in the field.
• Suicidality: Ketamine has rapid anti-suicidal effect signals in the literature; Spravato's product label includes data on reduction in depressive symptoms in patients with active suicidal ideation.

The evidence does not say "psychedelic-assisted therapy will fix them." It says: for specific conditions, in supervised settings, with preparation and integration, a meaningful proportion of patients show improvement. Some do not respond. Some show partial response. Durability varies, and follow-up care is part of the picture.

For condition-specific depth, ask the clinical team about treatment-resistant depression, PTSD, end-of-life distress, and suicidality.

---

Contraindications a family member should know about

The clinical team screens for contraindications at intake. As a family member, it helps to know the main ones, because you may be aware of history the patient has not surfaced:

• Personal or family history of psychosis (schizophrenia, schizoaffective disorder), a contraindication to psilocybin and MDMA; requires careful clinical consideration with ketamine.
• Bipolar I disorder: active mania or a history of mania is a contraindication or requires specialist oversight. The clinical team assesses this individually.
• Pregnancy or breastfeeding: psilocybin and MDMA are contraindicated; ketamine and esketamine also excluded. Pregnancy is a standard exclusion criterion in psychedelic-assisted therapy clinical trials. If your loved one may be pregnant, this is relevant information for their physician.
• Uncontrolled cardiovascular conditions: all four substances can produce transient blood pressure and heart rate elevation; uncontrolled hypertension and certain cardiac conditions are screened at intake.
• Active or recent substance-use disorder: screened at intake; some presentations are exclusions; others are managed on a case-by-case basis.

If you are aware of any of these in your loved one's history and are not sure they have disclosed it to the clinical team, the appropriate path is to encourage your loved one to discuss it with their physician, not to call the clinic yourself. Capacitous adults make their own medical decisions.

---

How the treatment process is structured

Understanding the structure helps you support your loved one without overstepping.

1. Intake and screening: medical history, medications, mental health history, suitability assessment. Some people are screened out; that is appropriate clinical practice.
2. Preparation phase: typically several sessions before the first dosing day, building rapport, setting intention, reviewing what to expect.
3. Dosing day(s): the medication session. Duration varies: ketamine approximately 1–2 hours of dissociative effect plus monitoring; Spravato approximately 2 hours observation; psilocybin approximately 6–8 hours; MDMA approximately 6–8 hours.
4. Integration phase: sessions in the days and weeks after dosing to process the experience and translate it into durable change.
5. Maintenance and follow-up: ongoing care, including continuation of existing treatments and psychotherapy.

---

Practical support: what you can actually do

Before the dosing day

• Help with logistics: appointment scheduling, paperwork, transport planning.
• Arrange a calm, low-demand environment for the 24–48 hours after the session.
• Offer emotional presence before the session; pre-session anxiety is common. Reassurance about the supervised setting is appropriate.
• Do not pressure them about what they "should" experience, predict outcomes, or impose your own beliefs about what the medicine will do.

Day of the dosing session

• Drive them to the session and confirm the return pickup plan with the clinic in advance.
• Drive them home. This is the core practical task. The 24-hour no-driving rule applies to all dissociative and psychedelic dosing, ketamine, esketamine, psilocybin, and MDMA. Your loved one cannot drive themselves, ride a bike, or operate machinery for at least 24 hours after dosing.
• Keep the post-session environment calm: low stimulation, meals ready, minimal demands.

Can I be in the room during dosing?

For most adult patients in standard (non-dyadic) protocols: no. The dosing space is for the patient and the trained therapist. This is a clinical setting, not a family setting. The patient's interior process needs space from family-system dynamics.

Exceptions and adjacent formats:

• Couples and dyadic psychedelic-assisted therapy: both partners are patients; the work is explicitly couples therapy. This is a different protocol. See Couples and Dyadic Psychedelic-Assisted Therapy.
• End-of-life distress with family presence: in some palliative-care-coordinated psilocybin cases, family presence at parts of the session may be clinically appropriate. This is decided case by case.

After the session, the first 24–48 hours

• Stay accessible: you do not need to hover, but be reachable.
• Provide a quiet environment: many people are tired, emotionally raw, or still processing.
• Light food and hydration.
• Do not push for a download. Let them talk if they want to; do not interrogate.
• Watch for warning signs: persistent suicidal thinking, prolonged confusion or dissociation, severe anxiety, sleep disruption beyond 48 hours. If present, call the clinic. If acute, use the crisis resources at the top of this page.

Integration phase, the weeks after

• Ongoing emotional support; integration is where the experience becomes durable change.
• Respect the therapy relationship, your loved one's integration sessions are with their therapist; you are supportive, not central.
• Notice patterns and share observations if useful, without prescribing what they mean.
• Be patient with non-response or partial response, this is part of the work.

---

What family members should NOT do

• Do not interpret the experience for the patient. Psychedelic and dissociative experiences are autobiographical to the person who had them. Let theirs be theirs.
• Do not pressure for outcomes. "Do you feel better yet?" repeated daily produces pressure, not improvement.
• Do not demand session details. They may share; they may not. Either is appropriate.
• Do not impose your spiritual or metaphysical framework. Let them describe their experience in their own terms.
• Do not compare to other people's stories. Your friend's experience is not a rubric.
• Do not second-guess the clinical team. If you have legitimate concerns, encourage the patient to raise them with their physician.
• Do not undermine their existing treatment. Medication and therapy decisions are between the patient and their clinical team.
• Do not share their mental health information. The patient's care is theirs to disclose.

---

When to seek urgent help

Contact the clinic if:

• Your loved one is in significant distress more than 48–72 hours after a session.
• They are confused, dissociated, or not recognizing their surroundings.
• They are not sleeping or eating for more than two days after the session.
• You observe concerning behavioural changes that feel out of character.

Use the crisis resources above (9-8-8, Talk Suicide Canada, 911) if:

• Your loved one expresses suicidal intent or you assess imminent risk of self-harm.
• They are in immediate danger.

Difficult experiences happen in supervised settings. They are not the same as treatment failure. If your loved one comes home distressed: stay calm and present, reduce stimulation, offer hydration and food, and call the clinic if distress is severe or persistent.

---

If they do not respond

Non-response is real and it is not a personal failure. Treatment-resistant conditions have multiple pathways. If psychedelic-assisted therapy does not produce the hoped-for response:

• The patient and clinical team discuss next steps together.
• Other modalities remain available: different medication classes, ECT, rTMS, intensive psychotherapy formats.
• Re-dosing protocols exist for some indications (Spravato has explicit maintenance dosing; physician-initiated psilocybin authorization requests can be re-submitted).

Your role: do not catastrophize, do not blame the patient, do not blame yourself, and do not blame the clinic.

---

End-of-life distress, supporting a loved one with life-limiting illness

If your loved one has cancer or another life-limiting illness and is considering psilocybin through Health Canada's case-by-case authorization for end-of-life distress, your role is particularly meaningful:

• Coordinate with the palliative care team, psilocybin for end-of-life distress is most appropriately integrated with the palliative team.
• You may already be the primary caregiver; the dosing day adds logistics to an already demanding situation.
• In some end-of-life distress cases, family presence at parts of the protocol may be appropriate, decided clinically, case by case.
• Your own grief and anticipatory loss are part of the picture. Bereavement support before and after death is appropriate.

---

Caregiver self-care, your mental health matters

Supporting someone with treatment-resistant depression, PTSD, or end-of-life distress is hard, sustained work. Caregiver burden is well-documented. You are not selfish for needing your own support.

• Your own therapist: many family members of patients in serious mental health treatment benefit from individual therapy.
• CMHA (Canadian Mental Health Association): branches across all provinces offer family education, support groups, and counselling: CMHA Ontario, CMHA BC, CMHA Alberta, and provincial equivalents.
• Provincial caregiver support: Ontario Caregiver Organization, Caregivers Alberta, Family Caregivers of BC.
• Peer support groups: Mood Disorders Society of Canada and CMHA branches offer condition-specific family support.
• Bereavement support: for end-of-life distress contexts, bereavement counselling before and after death is appropriate.

The 9-8-8 line is for you, too. Talk Suicide Canada (1-833-456-4566) takes calls from family members. You do not have to be the person in crisis to call.

---

How ATMA CENA works with families

• Information call: family members are welcome, with the patient's consent. Book an information call.
• Preparation phase: family and caregiver coordination as clinically appropriate.
• Dosing day: transport coordination is supported; family presence in the dosing space is generally not part of standard protocols, with the exceptions described above.
• Integration phase: family role is supportive, with clinical care led by the integration therapist.
• CoCare model: through ATMA CENA's CoCare program, the clinic can partner with the patient's existing therapist if that therapist has the appropriate training, through a service agreement. See CoCare.
• Referral to family support resources: when caregiver burden is significant, ATMA CENA can route to appropriate family support services.

---

Frequently asked questions

Is psychedelic-assisted therapy approved in Canada?

Spravato (esketamine) is Health Canada-approved for treatment-resistant depression and is recommended for adults under 65 [Health Canada 2025]. Off-label ketamine is widely used in psychiatric practice. Psilocybin and MDMA are accessed only through Health Canada's case-by-case, physician-initiated authorization and are investigational, not generally available outside that pathway, clinical trials, or the rare individual exemptions.

Will it fix them?

Honest answer: it may help, may produce partial response, or may not produce a response. It is part of ongoing care, not a one-shot fix. The evidence supports meaningful improvement for a meaningful proportion of patients with specific conditions in supervised settings.

Can I sit in on the dosing session?

For most adult patients in standard formats: no. The dosing space is for the patient and trained therapist. Exceptions include couples and dyadic formats, some end-of-life distress contexts, and other clinically-decided situations.

Can I drive them home?

Yes, and you should plan to. The 24-hour no-driving rule applies to all dissociative and psychedelic dosing.

Should I ask them about their experience?

Be available; do not interrogate. Let them lead. If they choose not to share, that is their right. The integration work happens with their therapist.

What if they have a difficult experience?

Stay calm, stay present, reduce stimulation, offer hydration and food. Call the clinic if distress is severe or persistent. Difficult experiences in supervised settings are not the same as treatment failure.

What if they don't respond?

Non-response is part of the picture for treatment-resistant conditions. The clinical team will discuss next steps. Do not catastrophize; do not assign blame.

Will they need ongoing therapy after?

Almost always yes. Integration is the work that translates the dosing experience into durable change. Ongoing psychotherapy is part of the protocol, not an add-on.

Can I attend the information call with them?

Yes, ATMA CENA welcomes family members at information calls, with the patient's consent. Book an information call.

What if they're suicidal?

Use the crisis resources at the top of this page. 9-8-8 call or text, Talk Suicide Canada 1-833-456-4566, or 911 for imminent danger.

What about spirituality or religion?

The patient leads. Do not impose your framework on their experience. Their interpretation of what happened belongs to them and to their therapist.

Will insurance cover this?

Spravato has the most established coverage pathways, including several major private insurers with prior authorization. Ketamine-assisted therapy is predominantly out-of-pocket, with some exceptions (for example, Veterans Affairs Canada coverage and public hospital programs). At ATMA CENA, ketamine-assisted therapy is priced at $1,590 for the initial treatment and $800 for each additional medicine session, with multi-session packages ranging from $2,390 to $6,500 and a $300 non-refundable deposit to begin intake. Psilocybin access is predominantly out-of-pocket. See ketamine therapy cost in Canada for detail.

What if I am worried about the clinic?

Verify credentials (provincial physician college, regulated psychotherapist licensure), ask about supervision protocols, and ask about complaint pathways. A reputable Canadian clinic will answer these questions transparently.

---

Compliance disclaimer

This article is educational and is not a substitute for individual clinical advice. Ketamine is approved by Health Canada as an anaesthetic; use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators (e.g., CPSA in Alberta, CPSO in Ontario, CPSM in Manitoba). Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression as of May 2020 and is not recommended for initiation in patients 65 years of age and older [Health Canada 2025]. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act (Schedule III and Schedule I respectively). Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada authorization on a case-by-case basis, initiated by a physician, and is not guaranteed. This access is primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness (psilocybin), or PTSD (MDMA). Nothing in this article constitutes a clinical recommendation for a specific individual; clinical decisions rest with a qualified treating physician.

---

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

---

Sources

1. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
2. Anand A, Mathew SJ, Sanacora G, et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 388(25):2315-2325. PMID: 37224135. https://www.nejm.org/doi/full/10.1056/NEJMoa2302307
3. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6):1025-1033. PMID: 33972795. https://www.nature.com/articles/s41591-021-01336-3
4. Mitchell JM, Ot'alora GM, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10):2473-2480. PMID: 37709999. https://www.nature.com/articles/s41591-023-02565-4
5. Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12):1181-1197. PMID: 27909164.
6. Ross S, Bossis A, Guss J, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12):1165-1180. PMID: 27909165.
7. Health Canada (2025). Spravato (esketamine) Product Monograph. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
8. Health Canada (2022). Notice to stakeholders: Requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
9. 9-8-8 Suicide Crisis Helpline (Canada). https://988.ca/
10. Canadian Mental Health Association (CMHA), National. https://cmha.ca/

---

Related articles

• CoCare, Coordinated Care Model, how ATMA CENA works alongside existing providers
• Couples and Dyadic Psychedelic-Assisted Therapy, when the relationship itself is the work
• Older Adults and Psychedelic-Assisted Therapy, supporting an aging parent

---

Last updated: 2026-05-28. Article reviewed every 6 months.